key: cord-0014105-x49e0312
authors: KC, Govinda; Bocci, Giovanni; Verma, Srijan; Hassan, Mahmudulla; Holmes, Jayme; Yang, Jeremy; sirimulla, suman; Oprea, Tudor I.
title: REDIAL-2020: A Suite of Machine Learning Models to Estimate Anti-SARS-CoV-2 Activities
date: 2020-09-16
journal: ChemRxiv
DOI: 10.26434/chemrxiv.12915779
sha: eaeb169ec208d2921026b5d47cf548f0d4c2a4d2
doc_id: 14105
cord_uid: x49e0312

Strategies for drug discovery and repositioning are an urgent need with respect to COVID-19. We developed "REDIAL-2020", a suite of machine learning models for estimating small molecule activity from molecular structure, for a range of SARS-CoV-2 related assays. Each classifier is based on three distinct types of descriptors (fingerprint, physicochemical, and pharmacophore) for parallel model development. These models were trained using high throughput screening data from the NCATS COVID19 portal (https://opendata.ncats.nih.gov/covid19/index.html), with multiple categorical machine learning algorithms. The “best models” are combined in an ensemble consensus predictor that outperforms single models where external validation is available. This suite of machine learning models is available through the DrugCentral web portal (http://drugcentral.org/Redial). Acceptable input formats are: drug name, PubChem CID, or SMILES; the output is an estimate of anti-SARS-CoV-2 activities. The web application reports estimated activity across three areas (viral entry, viral replication, and live virus infectivity) spanning six independent models, followed by a similarity search that displays the most similar molecules to the query among experimentally determined data. The ML models have 60% to 74% external predictivity, based on three separate datasets. Complementing the NCATS COVID19 portal, REDIAL-2020 can serve as a rapid online tool for identifying active molecules for COVID-19 treatment. The source code and specific models are available through Github (https://github.com/sirimullalab/redial-2020), or via Docker Hub (https://hub.docker.com/r/sirimullalab/redial-2020) for users preferring a containerized version.

Currently, there is an urgent need to find drugs and effective treatment options for coronavirus disease 2019 . Here, we present a suite of machine learning (ML) models termed "REDIAL-2020" that forecast activities for live viral infectivity, viral entry, and viral replication, specifically for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). This application can serve the scientific community when prioritizing compounds for in vitro screening and may ultimately accelerate the identification of novel drug candidates for the COVID-19 treatment. REDIAL-2020 currently consists of six independently trained ML models and includes a similarity/substructure search module that queries the underlying experimental dataset for similar compounds. These ML models were trained using experimental data generated by the following assays: the SARS-CoV-2 cytopathic effect (CPE) assay and its host cell cytotoxicity counterscreen; the Spike-ACE2 protein-protein interaction (AlphaLISA) assay and its TruHit counterscreen, as well as an angiotensinconverting enzyme 2 (ACE2) enzymatic activity assay; and 3C-like (3CL) proteinase enzymatic activity assay.

The assays represent three distinct categories: i) viral entry (CPE 1 and host cell cytotoxicity counterscreen 2 );

ii) viral replication (3CL enzymatic activity); and iii) live virus infectivity (AlphaLISA, TruHit counterscreen, and ACE2 enzymatic activity), 3 as described in the National Center for Advancing Translational Sciences (NCATS) COVID-19 portal. 4 We retrieved these datasets from the NCATS COVID19 portal. 5 The NCATS team is committed to performing a range of COVID19-related viral and host target assays, as well as analyzing the results. 6 These ML models are integrated into a user-friendly web portal that allows input using three different formats: i) drug name, both as International Nonproprietary Name, INNs (e.g., hydroxychloroquine) or as trade name (e.g., Plaquenil); ii) PubChem CID, 7 i.e., PubChem Compound ID number (e.g., 3652 for hydroxychloroquine); or iii) using the chemical structure encoded in the SMILES (Simplified Molecular-Input Line-Entry System) format, 8 respectively. The workflow and output, regardless of input format, is identical and described below.

Drug repositioning requires computational support, 9 and data-driven decision making offers a pragmatic approach to identifying optimal candidates while minimizing the risk of failure. Since molecular properties and bioactivities can be described as a function of chemical structure, cheminformatics-based predictive models are becoming increasingly useful in drug discovery and repositioning research. Specifically, anti-SARS-CoV-2 models based on high throughput data could be used as a prioritization step when planning experiments, particularly for large molecular libraries, thus decreasing the number of experiments and reducing downstream costs. REDIAL-2020 could serve such a purpose and help the scientific community reduce the number of molecules before experimental tests for anti-SARS-CoV-2 activity. This suite of ML models can also be used via the command line for large scale virtual screening. As more reliable data sets become available in the public domain, we plan to tune the ML models further, add additional models based on SARS-CoV-2 assays, and make these models available in future releases of REDIAL-2020.

The SARS-CoV-2 cytopathic effect (CPE) assay measures the ability of a compound to reverse the cytopathic effect induced by the virus in Vero E6 host cells. As cell viability is reduced by viral infection, the CPE assay measures the compound's ability to restore cell function (cytoprotection). While this assay does not provide any information concerning the mechanism of action, it can be used to screen for antiviral activity in a highthroughput manner. However, there is the possibility that the compound itself may exhibit a certain degree of cytotoxicity, which could also reduce cell viability. Since this confounds the interpretation of CPE assay results, masking the cyto-protective activity, a counter-screen to measure host (Vero E6) cell cytotoxicity is used to detect such compounds. Thus, a net, positive result from the combined CPE assays consists of a compound showing a protective effect but no cytotoxicity.

The Spike-ACE2 protein-protein interaction (AlphaLISA) assay measures a compound's ability to disrupt the interaction between the viral Spike protein and its human receptor protein, ACE2 (angiotensin-converting enzyme type 2). 10 The surface of the ACE2 protein is the primary host factor recognized and targeted by SARS-CoV-2 virions. 11 This binding event between the SARS-CoV-2 Spike protein and the host ACE2 protein initiates binding of the viral capsid and leads to viral entry into host cells. Thus, disrupting the Spike-ACE2 interaction is likely to reduce the ability of SARS-CoV-2 virions to infect host cells. This assay has two counterscreens, as follows. The TruHit counterscreen is used to determine false positives, i.e., compounds that interfere with the AlphaLISA readout in a non-specific manner, or with assay signal generation and/or detection. It uses the biotinstreptavidin interaction (one of the strongest known non-covalent drug-protein interactions) because other compounds are unlikely to disturb it. Consequently, any compound showing interference with this interaction is most likely a false positive. Common interfering agents are oxygen scavengers or molecules with spectral properties sensitive to the 600-700 nm wavelengths used in AlphaLISA. The second counterscreen is an enzymatic assay that measures human ACE2 inhibition to identify compounds that could potentially disrupt endogenous enzyme function. ACE2 lowers blood pressure by catalyzing the hydrolysis of angiotensin II (a vasoconstrictor peptide) into the vasodilator angiotensin (1-7). 12 While blocking the Spike-ACE2 interaction may stop viral entry, drugs effective in this manner could cause unwanted side-effects by blocking the endogenous vasodilating function of ACE2. Thus, the ACE2 assay serves to detect such eventualities and to derisk such off-target events.

Following entry into the host cell, the main SARS-CoV-2 replication enzyme is 3C-like proteinase (3CL), also called "main protease" or Mpro, 13 which cleaves the two SARS-CoV-2 polyproteins into various proteins (e.g., RNA polymerases, helicases, and methyltransferases, etc.), which are essential to the viral life cycle. Since inhibiting the 3CL protein disrupts the viral replication process, this makes 3CL an attractive drug target. 14 The SARS-CoV-2 3CL biochemical assay measures compounds' ability to inhibit recombinant 3CL cleavage of a fluorescently labeled peptide substrate.

Note on assays and models terminology. Throughout this paper, we refer to assay and model names as follows:

"CPE" for SARS-CoV-2 cytopathic effect, "cytotox" for host cell cytotoxicity counterscreen, "AlphaLISA" for Spike-ACE2 protein-protein interaction, "TruHit" for Spike-ACE2 protein-protein interaction counterscreen, "ACE2" for ACE2 enzymatic activity and "3CL" for 3CL enzymatic activity.

Prior to developing ML models, unsupervised learning should be used to evaluate the data and seek patterns that might guide successive steps. Hence, upon definition of the experimental categories (see Methods for details), we inspected the data using principal component analysis (PCA) 15 and applied it using VolSurf+ 16 molecular descriptors. For both CPE and cytotox, clusters emerge along the first principal component (PC1; Figure 1 ). For CPE data, the majority of compounds showing high to moderate CPE activity are grouped in the right-hand of Figure 1A . At the same time, compounds with high to moderate cytotoxicity are grouped in the right-hand region of Figure 1B . By inspecting the loading score plot for VolSurf+ descriptors that are likely to contribute to these patterns, we identified membrane permeability (estimated using logP, the logarithm of the octanol/water partition coefficient) and water solubility (estimated using logS, the logarithm of the thermodynamic aqueous solubility) as major contributors to the first latent variable (see Supporting Information Figure SI1 ). Compounds with low logP/high logS, clustered in the left-hand region of the score plot, are less likely to be active in the CPE assay and more likely to be non-cytotoxic.

The distribution of actives was also visualized for AlphaLISA and TruHit compounds in Figures 1C and 1D , respectively (see also Table 1 ). For the AlphaLISA assay, although clustering is less pronounced respect to CPE (Figure 1A) , the right-hand part of the plot does capture most of the high/moderate activity compounds.

Such distribution of actives in the right-hand region was not observed for ACE2 actives ( Figure 1E) . Thus, permeability and solubility are not the major determinants of this ACE2 inhibition assay.

The results of this preliminary analysis can be used to filter input data prior to machine learning. For example, the majority of the compounds placed on the left side of the Figure 1 PCA plot are inactive (exception for ACE2). Therefore, prior to developing the ML models, we applied cutoff filters based on compounds calculated logP and logS using ALOGPS 17 to every dataset except for ACE2. These filters help narrow the focus of ML model development on features derived only from compounds for which simple property criteria (e.g., logP and logS) cannot be used to distinguish actives from inactives --specifically, the right-hand regions in Figure 1 .

The initial number of compounds, after data wrangling, was 4,954. Upon use of the logS and logP filters, each dataset was reduced in size (Table 1) . However, the fraction of active compounds excluded from the ACE2 dataset was quite high (34%). Hence, logP and logS filters were not applied for ACE2 inhibition, and the complete dataset was used for model development. For 3CL enzymatic activity, data from NCATS was retrieved separately. The initial set contained 12,263 compounds. However, data wrangling identified ~1,850 duplicate and ~3,000 "inconclusive" entries, which were discarded. Additional entries were removed during the desalting and physicochemical feature generation as VolSurf descriptors could not be computed for some of the compounds. The final 3CL dataset contains 6,961 entries, with 222 active and 6,739 inactive compounds. Given that the fraction of active 3CL compounds filtered would have been 30%, the logP/logS filters were not applied.

There were no significant activity clusters detected in the 3CL dataset via PCA-VolSurf+ (see Supporting Information Figure SI2 ).

With respect to actives vs. inactives, the six NCATS assays are highly unbalanced, with a disproportionate ratio of active (few) compounds compared to inactive (many) compounds. For example, there were ~9 times more inactives than actives and ~3 times more non-cytotoxic compounds than cytotoxic compounds for the CPE and cytotoxicity assays, respectively. Thus, in order to avoid over-training for the dominant category, each model was derived using random selection wherein compounds from the majority class were selected in equal proportion to those of the minority class. Our balanced dataset numbers were as follows: 736 for CPE, 1,662 for cytotox, 1,260 for AlphaLISA, 1,668 for TruHit, 206 for ACE2 and 442 for 3CL. 

To evaluate anti-SARS-CoV-2 activities of novel chemicals, we implemented six predictive models based on consensus methods. Of the two consensus methods (voting-based and probability score-based) evaluated, the voting- were implemented as consensus models with the rdkit descriptors, with the remaining two (AlphaLISA and ACE2)

implemented as rdkit descriptor-based only. Tables 1 and 2 summarize the evaluation scores and the confusion matrices, respectively, for all models implemented in REDIAL-2020. 

By accessing REDIAL-2020 (http://drugcentral.org/Redial) from any web browser, including mobile devices, the submission page is displayed (Figure 4) . The web server accepts SMILES, drug names, or PubChem CIDs as input. The User Interface (UI) at the top of the page allows users to navigate various options (Figure 4) . The

UI provides summary information about the six models, such as model type, which descriptor categories were used for training, and the evaluation scores. The UI further depicts the processes of cleaning the chemical structures (encoded as SMILES) prior to training the ML models. Input queries such as drug name and PubChem CID are converted to SMILES prior to processing. Each SMILES string input is subject to four different steps, namely, converting the SMILES into canonical SMILES, 19 active in the AlphaLISA assay but d) inactive in the TruHit assay while e) not blocking ACE2; or f) active in the 3CL assay; or any combination of the above three. A schematic representation of the "best profile" that can be defined for a molecule, after running all the prediction models, is depicted in Figure 6 . 

For each query molecule, a fingerprint-based Tanomoto 22 similarity search is conducted against molecules included in the model input datasets. For reference, we have used datasets from the NCATS COVID19 portal 5 for the similarity search. The top 10 similar molecules to that of the query molecule, based on Tanimoto coefficient 23 scores, are displayed (see Figure 5 ). 

To confirm the utility of our models, we collected three additional datasets from the literature and submitted these molecules (external to our training/test sets) as input for prediction. First, we used a recently developed database for COVID-19 experiments 24 to explore and download published in vitro COVID-19 bioactivity data for approved drugs which was reported in various recent papers. 13, [25] [26] [27] [28] [29] [30] [31] [32] After removing drugs already included in the NCATS experiments, we identified 39 external drugs active in anti-SARS-CoV-2 CPE assays (Supporting Information Table SI1 ). Out of 39 drugs, 24 were predicted as active by at least two models and by the consensus model (Figure 7) , and 15 drugs were predicted as inactive. Among those predicted to be inactive, independent experiments suggest they are weakly The second external CPE set was collected from a recently published screen that included 21 compounds from the ReFRAME library, 33 validated in dose response across multiple cell lines. 32 Out of 21 most potent compounds, 19

were identified as an external set to our CPE model (Supporting Information The consensus model predicts all potent (activity less than 2µM) compounds correctly inhibitors, namely ebselen, tideglusib, and carmofur, respectively.

Thus, the REDIAL-2020 suite of models correctly predicts ~60% of the external compounds for the CPE assay, 74%

of the external compounds for the ReFRAME library, 33 and 66.67% of the external compounds for 3CL inhibitors 13 , respectively. Although these values appear to underestimate previous model performance in the validation and external sets (see Table 3 ), it has been noted that CPE experiments are affected by significant intra-and interexperiment variability. 24 Hence, we cannot exclude the possibility that some of the experiments performed by other laboratories are not directly comparable with results from the NCATS COVID19 portal. 5 

Here, we described "REDIAL-2020", an open-source, open-access, open-science application for estimating anti-SARS-CoV-2 activities from molecular structure. By leveraging the recently available data from NCATS, we developed six categorical ML models: CPE, cytotox, AlphaLISA, TruHit, ACE2, and 3CL. Input data from NCATS were used to train and validate multiple ML models using a variety of algorithms and features. The best performing models, in terms of F1 scores and test set predictions, were exposed on the REDIAL-2020 portal. Furthermore, a similarity search against the input data is conducted for every submitted molecule. The top 10 most similar molecules to the query molecule from the existing COVID-19 databases, together with associated experimental data, are displayed. This allows users to evaluate the confidence of the ML predictions.

REDIAL-2020 provides a fast and reliable way to screen novel compounds for anti-SARS-CoV-2 activities. These would be compounds that block live virus infectivity (CPE active but not cytotoxic); or compounds that block viral entry (blocking the Spike/ACE2 interaction while not interfering with the assay and lacking ACE2 inhibition properties); or compounds that block viral replication, by inhibiting 3CL (Mpro) protease; or a combination of the above, respectively. REDIAL-2020 is available on Github and Dockerhub as well, and the command-line version supports large scale virtual screening purposes. Future developments of REDIAL-2020 could include additional ML models based on, e.g., newly released TMPRSS2 inhibition assay 34 data from the NCATS COVID19 portal, and perhaps other assay data as they become available in the public domain. We will continue to update and enhance the ML models, and make these models available in future releases of REDIAL-2020.

Data for the SARS-CoV-2 cytopathic effect (CPE), the Vero E6 (host cell) cytotoxicity counterscreen, the Spike-ACE2 protein-protein interaction (AlphaLISA), TruHit (AlphaLISA counterscreen), ACE2 enzymatic inhibition conterscreen, and 3CL enzymatic inhibition were obtained from the NCATS COVID19 portal. 4, 5 Assay data were mapped to DrugCentral2020 to retrieve DrugCentral IDs, SMILES strings, and drug names. The experimental results from NCATS were mined to define activity and significance classes. The procedure for data extraction, wrangling, and post-processing are detailed as follows.

All operations described below were performed using the Knime 35 platform. NCATS data associated with the aforementioned assays was downloaded from the COVID19 portal. 4 were stored. Whenever possible, for approved drugs and other chemicals, SMILES were retrieved from DrugCentral and from PubChem, respectively. Otherwise, the original SMILES strings were retained. Bioactivity data was mined according to the "curve class" and "maximum response" parameters. 37 The "curve class" evaluates the quality of the dose-response curve and, consequently, the quality of the measurement. The "maximum response" is the maximum response value detected during the experiment. The "ACTIVITY CLASS" and a "SIGNIFICANCE CLASS" were defined using criteria described in Table 4 and Table 5 , respectively. As a final data wrangling step, all compounds were categorized, and assay data grouped to have a unique record per molecule for each assay. When more than one assay was measured for the same molecule, only the datapoint with the best curve class was retained. 

For each assay, the data was labeled as positive and negative. The compounds with "LOW" activity class were treated as negative, whereas "HIGH" and "MODERATE" were treated as positive compounds. Molecular structures were standardized using five different filters using RDKit 38 features: (i) SMILES strings were converted into canonical SMILES strings. Some of the SMILES were not converted SMILES, were discarded. (ii) RDKit Salt Stripper was implemented to obtain the salt stripped molecules. The "donotRemoveEverything" feature helps by leaving the last salt when the entire canonical SMILES string contains only the salts, (iii) The RDKit "Uncharger" feature neutralizes the molecules by adding or removing hydrogen atoms, (iv) The canonical tautomer was used obtained from RDKit, and (v) logP and logS filters were defined as follows: (logP < 1 and logP > 9) and (logS > -3 and logS < -7.5). Such thresholds were arbitrarily defined to maximize the number of negative data excluded while minimizing the positive data excluded. However, for the 3CL dataset, logP and logS filters were not implemented. The final task was the removal of duplicate compounds resulting from desalting, neutralizing, and standardizing tautomers.

A total of 22 features of three distinct types (fingerprints-based, pharmacophore-based, and physicochemical descriptors based) were implemented. Fingerprints were converted into a bit vector of either 1,024 or 16,384 lengths.

Pharmacophore type was also a bit vector of size 2,692, whereas RDKit and VolSurf+ descriptors were of length 200 and 128, respectively.

This includes the circular, path-based, and substructure keys. 39 Pharmacophore-based: Topological pharmacophore atomic triplets fingerprints (TPATF) were obtained using maychemtools. 41 (Figure 7) were not part of this workflow and are not included in Table 6 . 

We used an ECFP4 bit vector fingerprint with 1024 bits, and TC calculations, for the fingerprints present in the database along with that of a query molecule, are computed on the fly. The Tanimoto coefficient represents the overlap of features between molecules as the ratio of the number of common features to the total number of features in each fingerprint. The coefficient ranges from 0 to 1, with 1 corresponding to identical fingerprints.

The best performing default models based on validation sets were selected for hyperparameter optimization. These models were optimized using a grid search method. Scikit-learn provides the package for grid search hyperparameter optimization using cross validation. However, it is slow and does not offer a grid search with a separate validation set.

Thus, we used a freely available software "hypopt" for the hyperparameter tuning of each model. 44 The models were optimized and selected based on the validation F1 score. The outperforming models were saved and used for the evaluation of external datasets.

The model performances were evaluated by five distinct evaluation metrics available in scikit-learn: accuracy, recall, precision, F1 score, and area under the receiver operating characteristic (ROC) curve (AUC). In general, the accuracy measures the total number of correct predictions among the total numbers of instances evaluated. The recall was used to measure the fraction of total positives that are correctly classified, whereas precision estimates the fraction of total positives that are correctly predicted from the total predicted positives. F1 score is the harmonic mean of recall and precision. The score ranges from 0 to 1 for each of the metrics, where 1 is a perfect score. Moreover, AUC was computed for each of the classifiers. A perfect classifier yields an AUC of 1, whereas a random model has an expected AUC of 0.5.

REDIAL-2020 is available online at http://drugcentral.org/Redial.

All of the codes and the trained models are available at https://github.com/sirimullalab/redial-2020.

The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators

Predictive models for estimating cytotoxicity on the basis of chemical structures

Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay

An OpenData portal to share COVID-19 drug repurposing data in real time

Massive-scale biological activity-based modeling identifies novel antiviral leads against SARS-CoV-2. bioRxiv

PubChem Substance and Compound databases

SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules

Associating drugs, targets and clinical outcomes into an integrated network affords a new platform for computer-aided drug repurposing

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells

A. ACE2 of the heart: from angiotensin I to angiotensin

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy

Principal component analysis. Alternative to referee methods in method comparison studies

VolSurf: a new tool for the pharmacokinetic optimization of lead compounds

Virtual computational chemistry laboratory--design and description

Scikit-learn: Machine learning in Python. the

SMILES. 2. Algorithm for generation of unique SMILES notation

DrugCentral 2018: an update

DrugCentral: online drug compendium

A Computer Program for Classifying Plants

Enhancing the effectiveness of virtual screening by fusing nearest neighbor lists: a comparison of similarity coefficients

The COVID-19 Gene and Drug Set Library

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs

FDA approved drugs with broad anticoronaviral activity inhibit SARS-CoV-2 in vitro

In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication

Reversal of Infected Host Gene Expression Identifies Repurposed Drug Candidates for

A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis

An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of

KNIME: the Konstanz Information Miner. Studies in Classification, Data Analysis, and Knowledge Organization

InChI, the IUPAC International Chemical Identifier

Handbook of Drug Screening

RDKit: Open-source cheminformatics

Open-source platform to benchmark fingerprints for ligand-based virtual screening

Extended-connectivity fingerprints

MayaChemTools: An Open Source Package for Computational Drug Discovery

Topological fuzzy pharmacophore triplets and adapted molecular similarity scoring schemes

A computational procedure for determining energetically favorable binding sites on biologically important macromolecules

We thank the High-Performance Computing support staff (Marc T. Hertlein and Leopoldo A. Hernandez) atThe University of Texas at El Paso for assistance in using the Chanti cluster. We also acknowledge the Texas